

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Arsenic trioxide for treating acute promyelocytic leukaemia [ID446]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

At the scoping stage, it was suggested that if the evidence did not support a recommendation, the committee should consider whether a higher ICER is acceptable to promote access to treatment in people who are Jehovah's witnesses. As the technology was recommended, this is not necessary. Therefore this is not an equality issue for this appraisal.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

It was highlighted that older people who cannot have chemotherapy would be eligible for treatment with arsenic trioxide. The committee agreed that its recommendations do not have a different impact on people protected by the equality legislation than on the wider population. Therefore this is not an equality issue for this appraisal.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other equality issues were identified by the committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes in section 3.19.

Approved by Associate Director (name): ...Frances Sutcliffe

Date: 26/04/2018